Hims & Hers Health, Inc. (NYSE:HIMS) Shares Acquired by Blume Capital Management Inc.

Blume Capital Management Inc. increased its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 100.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 1,200 shares of the company’s stock after buying an additional 600 shares during the period. Blume Capital Management Inc.’s holdings in Hims & Hers Health were worth $29,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Principal Financial Group Inc. raised its stake in Hims & Hers Health by 102.0% during the 3rd quarter. Principal Financial Group Inc. now owns 290,414 shares of the company’s stock valued at $5,349,000 after acquiring an additional 146,621 shares during the last quarter. State of New Jersey Common Pension Fund D lifted its position in Hims & Hers Health by 30.1% in the third quarter. State of New Jersey Common Pension Fund D now owns 123,587 shares of the company’s stock valued at $2,276,000 after purchasing an additional 28,600 shares during the period. Los Angeles Capital Management LLC raised its stake in shares of Hims & Hers Health by 40.8% during the 3rd quarter. Los Angeles Capital Management LLC now owns 40,353 shares of the company’s stock worth $743,000 after buying an additional 11,686 shares in the last quarter. Versor Investments LP acquired a new stake in shares of Hims & Hers Health in the 3rd quarter valued at approximately $634,000. Finally, Victory Capital Management Inc. boosted its stake in shares of Hims & Hers Health by 164.9% in the third quarter. Victory Capital Management Inc. now owns 51,577 shares of the company’s stock valued at $950,000 after buying an additional 32,108 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Buying and Selling

In other news, insider Michael Chi sold 17,303 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $48.14, for a total transaction of $832,966.42. Following the completion of the sale, the insider now directly owns 193,601 shares in the company, valued at $9,319,952.14. This represents a 8.20 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Andrew Dudum sold 78,127 shares of Hims & Hers Health stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $29.62, for a total value of $2,314,121.74. Following the completion of the transaction, the chief executive officer now directly owns 109,956 shares in the company, valued at $3,256,896.72. This represents a 41.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 969,191 shares of company stock worth $34,005,375. 17.71% of the stock is owned by insiders.

Hims & Hers Health Stock Down 7.3 %

Shares of NYSE:HIMS opened at $31.47 on Friday. The company has a market capitalization of $6.99 billion, a P/E ratio of 71.51 and a beta of 1.37. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98. The stock’s fifty day simple moving average is $38.36 and its 200-day simple moving average is $27.92.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on HIMS. TD Cowen reiterated a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Needham & Company LLC raised their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Piper Sandler boosted their price objective on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, February 25th. Bank of America reaffirmed an “underperform” rating and issued a $21.00 target price on shares of Hims & Hers Health in a report on Thursday, March 6th. Finally, Morgan Stanley lowered Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and an average target price of $37.23.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.